Biogen adds key manufacturing plant to its potentially quixotic aducanumab launch plan

Josh Sullivan

Biogen’s do-or-die review date for Alzheimer’s hopeful aducanumab is fast approaching, and the drugmaker has made it clear it will prep for a large commercial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen adds key manufacturing plant to its potentially quixotic aducanumab launch plan

Josh Sullivan

Sign up to read this article for free.

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat

Bio­gen adds key man­u­fac­tur­ing plant to its po­ten­tial­ly quixot­ic ad­u­canum­ab launch plan

Josh Sullivan

Sign up to read this article for free.

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Biogen adds key manufacturing plant to its potentially quixotic aducanumab launch plan

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat